Results 181 to 190 of about 19,412 (203)

Osimertinib

Reactions Weekly, 2020
  +6 more sources

Osimertinib

Reactions Weekly, 2017
  +5 more sources

Osimertinib

Reactions Weekly, 2023
  +4 more sources

Osimertinib

Reactions Weekly, 2019
  +5 more sources

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Annals of Oncology, 2022
Miklós Pless, Ernest Nadal, B Massutí   +2 more
exaly  

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis

Pharmacological Research, 2023
Zhaoxia Wang, Chenchen Wei
exaly  

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study

Journal of Thoracic Oncology, 2022
Ryo Toyozawa, Yasuto Yoneshima
exaly  

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Annals of Oncology, 2020
S S Ramalingam, M-J Ahn, M -J Ahn
exaly  

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Annals of Oncology, 2020
Y-L Wu, S S Ramalingam, V A Papadimitrakopoulou   +2 more
exaly  

Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: A case report

Clinical Case Reports (discontinued), 2022
Yuko Fukuda
exaly